Wednesday, August 28, 2019 12:40:50 PM
We can then add that upcoming medical journal to other recent events including:
• today’s robust & positive S1R publication in Frontiers (which references 2-73 and 3-71 specifically); and factor in all of the other recent positives including
• our new CMO in 2019 Dr Kaufmann (Rett Syndrome leading researcher),
• key job postings at indeed.com last week,
• our 2019 announced ERP Biomarker consortium with BP and Cognision
• our leadership role in precision medicine in the CNS space,
• Rett Syndrome trial DSMB review outcome received as a positive sign (per Janney Montgomery Scott analyst Yun Zhong),
• purchase of $1MM of 2-73 inventory
• “we are working with specialists” to develop a commercial name for 2-73 Blarcamesine,
• RS and PDD and AD researchers/participants asking to extend treatment in current trials and the ph2a trial,
• 4-5 years of safety with generally mild AE (indicative of compound crossing the BBB per Dr M)
• positive reported RWE in ph2a, as referenced in presentations and trial PI Macfarlane media quotes
• AD promising-efficacy especially when dose/blood concentration correlated per Ariana analysis
• according to q3 conf call, the Company believes (awaiting confirmation in current trials) that 2-73/blarcamesine is able to correlate with an improvement in gut microbiata levels (patients had a higher diversity in the gut)
Are US regulators being made aware of Anavex’s progress & the growing body of scientific support for our MOA across a WIDE RANGE of debilitating medical diseases and conditions??
If so, and in light of our long-term safety record and mild side effects and positive real world evidence, combined with the need to treat AD at the earliest stage possible, HOW/WHY are we not yet granted an accelerated approval pathway by the US Food & Drug Administration?
Where is the contradictory scientific evidence negating our MOA?
I can only find solid SUPPORT.
To invoke the great philosopher Michael Stipe from REM, it seems we are pushing an elephant up the stairs.
Pressure is building though, and it’ll likely come from the outside. Our trial patients/caregivers and trial PI’s & S1R worldwide researchers’ influence may someday tilt the scale.
https://www.frontiersin.org/articles/10.3389/fnins.2019.00862/full?utm_source=F-NTF&utm_medium=EMLX&utm_campaign=PRD_FEOPS_20170000_ARTICLE
Jobs at Anavex, driven by innovation, problem-solving and fast growth vision:https://www.indeed.com/jobs?q=anavex&l=
https://erpbiomarkers.org/
https://www.nasdaq.com/aspx/call-transcript.aspx?StoryId=4282937&Title=anavex-life-sciences-avxl-ceo-christopher-missling-on-q3-2019-results-earnings-call-transcript
https://www.frontiersin.org/articles/10.3389/fimmu.2018.02325/full#h2
[https://www.google.com/amp/s/finance.yahoo.com/amphtml/news/congress-big-pharma-money-123757664.html
“I’m really much more concerned because Congress is supposed to have oversight for the FDA,” Brown said. “If the FDA isn’t going to hold pharma accountable, and Congress is getting paid to not hold pharma accountable, then it really doesn’t matter who the president is because it’s really about Congress.”]
Recent AVXL News
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL • PR Newswire (US) • 04/16/2024 09:45:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/12/2024 09:45:00 AM
- Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference • GlobeNewswire Inc. • 04/11/2024 11:30:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/09/2024 09:45:00 AM
- Anavex Life Sciences Corporation Class Action: The Gross Law Firm Reminds Anavex Life Sciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 13, 2024 - AVXL • PR Newswire (US) • 04/05/2024 09:45:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 04/02/2024 09:45:00 AM
- Lost Money on Anavex Life Sciences Corporation(AVXL)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm • PR Newswire (US) • 03/29/2024 09:45:00 AM
- Investors who lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 03/26/2024 09:45:00 AM
- Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/25/2024 11:30:00 AM
- The Gross Law Firm Notifies Anavex Life Sciences Corporation Investors of a Class Action Lawsuit and Upcoming Deadline • PR Newswire (US) • 03/22/2024 09:45:00 AM
- Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia • GlobeNewswire Inc. • 03/18/2024 11:30:00 AM
- Anavex Life Sciences to Present at the 44th Annual TD Cowen Health Care Conference • GlobeNewswire Inc. • 02/26/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:05:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:04:32 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:04:31 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:03:48 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:03:06 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/07/2024 09:31:07 PM
- Anavex Life Sciences Reports Fiscal 2024 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/07/2024 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2024 First Quarter Financial Results on Wednesday, February 7th, 2024 • GlobeNewswire Inc. • 02/01/2024 12:30:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/25/2024 10:01:34 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM